Xenon Pharmaceuticals (XENE) Free Cash Flow (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Free Cash Flow data on file, last reported at -$89.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 44.31% year-over-year to -$89.0 million in Q1 2026; TTM through Mar 2026 was -$307.3 million, a 53.79% decrease from a year earlier, with the FY2025 full-year figure at -$279.9 million, down 51.75% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$89.0 million, down from -$81.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for XENE reached as high as -$17.4 million in Q2 2022 and fell as low as -$89.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$47.9 million across 5 years, with a median of -$46.4 million in 2024.
• Across the five-year window, Free Cash Flow rose 11.71% in 2022 and plunged 103.04% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$37.1 million in 2022, then rose by 4.32% to -$35.5 million in 2023, then slumped by 55.49% to -$55.2 million in 2024, then sank by 48.27% to -$81.8 million in 2025, then retreated by 8.84% to -$89.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$89.0 million in Q1 2026, -$81.8 million in Q4 2025, and -$72.0 million in Q3 2025.